ISPOR - The Budget Impact of Introducing Bg-12 (Dimethyl Fumarate) for Treatment of Relapse-Remitting Multiple Sclerosis (RRMS) in Canada

Full Text

The Budget Impact of Introducing Bg-12 (Dimethyl Fumarate) for Treatment of Relapse-Remitting Multiple Sclerosis (RRMS) in Canada

Abstract

Authors

E. Dorman A.R. Kansal S. Sarda

Back to Volume 16, Issue 7

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now